Drugs / NKR-2 CAR-T Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03612739 | Dec 2018 → May 2019 | acute myeloid leukemia, myelodysplastic syndrome | Celyad Oncology SA | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKR-2 CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03612739 ↗ |
| Modality | Cell therapy | “NKR-2 CAR-T Cells” NCT03612739 ↗ |